Zobrazeno 1 - 10
of 40
pro vyhledávání: '"A. Soto Matos-Pita"'
Autor:
Calvo, E., Moreno, V., Flynn, M., Holgado, E., Olmedo, M.E., Lopez Criado, M.P., Kahatt, C., Lopez-Vilariño, J.A., Siguero, M., Fernandez-Teruel, C., Cullell-Young, M., Soto Matos-Pita, A., Forster, M. *
Publikováno v:
In Annals of Oncology October 2017 28(10):2559-2566
Autor:
Thibaud Valentin, Jorge L. Iglesias, Arturo Soto Matos-Pita, Elena Elez, Josep Tabernero, Carlos Gomez-Roca, Teresa Macarulla, Salvador Fudio, Katrin Zaragoza, Guillem Argiles, Cinthya Coronado, Jean-Pierre Delord, Sarah Betrian
Publikováno v:
Investigational New Drugs. 37:674-683
Background Plocabulin (PM060184) is a novel marine-derived microtubule inhibitor that acts as an antitumor agent. This first-in-human study evaluated dose-limiting toxicities (DLT) to define the maximum tolerated dose (MTD) and phase II recommended d
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Michael Flynn, Carmen Kahatt, Martin Forster, A. Soto Matos-Pita, J.A. Lopez-Vilariño, Carlos Fernández-Teruel, Victor Moreno, Mariano Siguero, Martin Cullell-Young, Emiliano Calvo, M.E. Olmedo, Esther Holgado, M.P. Lopez Criado
Publikováno v:
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Annals of Oncology
Consejería de Sanidad de la Comunidad de Madrid
Annals of Oncology
Background Lurbinectedin (PM01183) has synergistic antitumor activity when combined with doxorubicin in mice with xenografted tumors. This phase I trial determined the recommended dose (RD) of doxorubicin (bolus) and PM01183 (1-h intravenous infusion
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::858dae5a703a11916820f3dbe5502204
https://hdl.handle.net/20.500.12530/30265
https://hdl.handle.net/20.500.12530/30265
Autor:
David Geary, Arturo Soto-Matos Pita, Carmen Kahatt, Sergio Szyldergemajn, Mark J. Ratain, Carlos Fernandez Teruel, Teresa Macarulla, Josep Tabernero, S. Peter Kang, Maria Elena Elez, Martin Cullell-Young, Mariano Siguero
Publikováno v:
Clinical Cancer Research. 20:2205-2214
Purpose: Lurbinectedin (PM01183) binds covalently to DNA and has broad activity against tumor cell lines. This first-in-human phase I study evaluated dose-limiting toxicities (DLT) and defined a phase II recommended dose for PM01183 as a 1-hour intra
Autor:
Judy Garber, J.A. Perez Fidalgo, Carmen Kahatt, Sergio Szyldergemajn, Cristian Fernandez, Nadine Tung, SJ Isakoff, Ana Lluch, J Balmaña, A Soto Matos-Pita, Cristina Cruz, J. Baselga
Publikováno v:
Cancer Research. 73:OT1-4
Background: MBC is a clinically heterogeneous disease that cannot be cured with currently available treatment options. Selective approaches are needed to identify patient subgroups with different tumor sensitivities who will benefit the most from ava
Autor:
E. Sicart, M. J. Carreras, Jaume Capdevila, Caroline O. Michie, Martin Cullell-Young, Sally Clive, C. Coronado, A. Soto Matos-Pita, Carmen Kahatt, A. Piera, C. Fernandez Teruel, Esther Casado, Josep Tabernero, Mariano Siguero
Publikováno v:
Cancer Chemotherapy and Pharmacology. 71:1247-1254
PM00104 (Zalypsis) is a synthetic tetrahydroisoquinoline alkaloid with potent antiproliferative activity against tumor cell lines. This phase I study evaluated the safety, dose-limiting toxicities (DLTs), recommended dose for phase II trials (RD), ph
Autor:
Mark J. Ratain, Jorge L. Iglesias, Martin Cullell-Young, David Geary, Arturo Soto Matos-Pita, Jennifer R. Diamond, Lia Gore, Manish R. Sharma, Sergio Szyldergemajn, Antonio Jimeno, Carlos Fernandez Teruel
Publikováno v:
Investigational new drugs. 35(4)
Background Lurbinectedin administered as a 1-h intravenous infusion every 3 weeks induces neutropenia, with the nadir usually occurring during the second week. This phase I study evaluated an alternative lurbinectedin dosing schedule consisting of a
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Martin Cullell-Young, Hernán Cortés-Funes, Luis Paz-Ares, A. Soto Matos-Pita, Beatriz Pardo, Esther Casado, C. Cuadra, Ramon Salazar, A. López-Martín, M. C. Garcia, J. L. Iglesias Dios, Josep Tabernero, Bernardo Miguel-Lillo, C. Coronado
Publikováno v:
Cancer chemotherapy and pharmacology. 72(1)
Kahalalide F (KF) is a dehydroaminobutyric acid-containing peptide from marine origin with activity against several human malignant cell lines. This dose-escalating phase I clinical trial evaluated the maximum tolerated dose (MTD), and the recommende